Association of blood cell counts with the risk of olanzapine‐ or clozapine‐induced dyslipidemia in Chinese schizophrenia patients. (4th July 2019)

• Record Type: Journal Article
• Authors: Xiong, Zongping; Cheng, Ming; Zhu, Peng; Huang, Shiqiong; Guo, Jun; Zhang, Wei; Zhou, Honghao; Shu, Yan; Li, Qing
• Is Part Of: Human psychopharmacology. Volume 34:Number 4(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-07-04
• Subjects: clozapine -- dyslipidemia -- olanzapine -- peripheral blood cells -- serum lipids; Psychopharmacology -- Periodicals; Psychotropic drugs -- Periodicals; Psychopharmacology -- Periodicals; Psychotropic Drugs -- pharmacology -- Periodicals; 615.78
• DOI: 10.1002/hup.2699
• Languages: English
• ISSNs: 0885-6222

Abstract

Abstract: Objective: The aim of this study was to investigate correlation of peripheral blood cell counts with the dyslipidemia induced by olanzapine or clozapine in Chinese schizophrenia patients. Methods: A total of 703 eligible schizophrenia patients were enrolled . The counts of red blood cell (RBC), platelet, white blood cell (WBC) and its subtypes, and serum lipids were determined for all participants before and after 2–4 weeks of olanzapine or clozapine treatment. Results: The two representative second‐generation antipsychotics (SGAs), olanzapine and clozapine, markedly caused dyslipidemia in Chinese schizophrenia patients. The tertiles of total RBC counts were positively associated with the odds of having abnormal triglyceride ( p < .01) and high‐density lipoprotein cholesterol (HDL‐C) levels (.05). The tertiles of platelet counts were also positively associated with the odds of having abnormal total cholesterol (.03), low‐density lipoprotein cholesterol ( p < .01), HDL‐C (.01), and non‐HDL‐C ( p < .01). However, the counts of WBC and its some subtypes were negatively correlated with the risk of dyslipidemia in these patients. Conclusion: The profile of peripheral blood cells may be an early biomarker for predicting the risk of metabolic disorders and cardiovascular diseases in schizophrenia patients treated with SGAs.